Illumina HiSeq 2500 paired end sequencing; Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES
Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES
The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB.  The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads.
Experimental Factor: Tyr::Cre;Tyr::NRASQ61K/; Trp53l/l
genotype
Experimental Factor: normal
disease